A phase I clinical trial evaluating the application of hydrogel in reducing rectal dose during cervical cancer brachytherapy
The application of the hydrogel effectively increased the distance between the cervix and rectum in brachytherapy for cervical cancer, limiting the rectal dose without increasing doses to other critical organs. In the short term, no severe adverse events were observed, indicating the safety and reliability of this approach. Further research is warranted to confirm its long-term safety and effectiveness.
Authors
- Hongnan Zhen (ORCID: https://orcid.org/0000-0002-3924-9183)
- Fuquan Zhang (ORCID: https://orcid.org/0000-0002-6856-2320)
- Yuxuan Wang (ORCID: https://orcid.org/0009-0002-5716-6776)
- Chunli Luo
- Lang Yu
- Jie Zhang
- Lihua Yu
- Junfang Yan (ORCID: https://orcid.org/0009-0006-2624-9869)
- Ke Hu (ORCID: https://orcid.org/0000-0003-3462-5378)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2024-09-21
- DOI
- https://doi.org/10.1016/j.ctro.2024.100867
- Citations
- 4
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- Peking Union Medical College Hospital
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine